BenevolentAI Acquires Facility for Artificial Intelligence-Enabled Drug Development
BenevolentAI, a London, UK-headquartered artificial intelligence (AI) company focused on drug development, has acquired a drug discovery and development facility on the Babraham Research Campus in Cambridge, UK for an undisclosed sum.
The acquisition creates an AI-enabled research center that is expected to reduce the time it takes for drug candidates to enter clinical testing and deliver higher success rates in treating or curing disease.
The company says it will be able to work across the drug development process as an ‘end-to-end’ provider from drug discovery to late-stage clinical development.
The acquired drug discovery and development facility has a scientific team with experience in assay development and screening, medicinal and synthetic chemistry, drug metabolism and pharmacokinetics, pharmacology, and clinical development.
BenevolentAI says its artificial intelligence technology has generated drug candidates to treat a range of diseases. The company has expanded its drug research pipeline to include 19 programs since establishing its drug-development subsidiary BenevolentBio less than two years ago.